98%
921
2 minutes
20
Background: The QIAGEN QIAsymphony(®) SP is an automated system that can process a variety of different sample types for nucleic acid extraction.
Objectives: To compare this system against the bioMérieux NucliSens easyMAG using a range of common clinical sample types.
Study Design: Nucleic acid extracts were tested on 6 in-house real time viral PCR assays: quantitative cytomegalovirus (CMV); respiratory and enteric multiplex (10 viruses); influenza A H1N1 2009 specific H1 and N1 assays (sH1/N1); herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus (VZV) multiplex; norovirus genogroups I and II (Noro GI/II) multiplex.
Results: Extraction of the clinical sample by either QIAsymphony(®) SP or NucliSens easyMAG gave similar results for each PCR; CMV viral loads, 52 plasma samples had a mean difference (easyMAG-QIAsymphony(®)) of 0.002 log(10)copies/ml (s.d. 0.536), 52 whole blood samples had a mean difference of -0.232 log(10)copies/ml (s.d. 0.490). Concordance for the qualitative assays were; 64/67 (95.5%) for the respiratory and enteric multiplex, all 28 (100%) for the sH1, sN1 and influenza A matrix multiplex, 33/34 (97%) for the HSV1/HSV2/VZV multiplex and all 15 (100%) for the Noro GI/II. Inter- and intra-run variation, determined for a 10-fold dilution series of CMV (5.20-3.20 log(10)copies/ml), was less than 0.63 log(10)copies/ml.
Conclusions: Our evaluation found the performance of the QIAsymphony(®) SP comparable to the NucliSens easyMAG for a range of sample types commonly extracted in a clinical virology laboratory. In total, 331/343 (96.5%) PCR results were concordant on samples extracted by both platforms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcv.2011.08.016 | DOI Listing |
J Microbiol Immunol Infect
June 2025
Laboratoire de Parasitologie-Mycologie, Plateforme de Biologie Hospitalo-Universitaire, 2 Rue A. Ducoudray, BP 37013, 21070, Dijon Cedex, France; Centre National de Reference des Cryptosporidioses, Microsporidies et Autres Protozooses Digestives, Laboratoire associe: Laboratoire de Parasitologie/myc
Background: Intestinal parasitic diseases affect millions of people worldwide. Numerous commercial molecular methods detecting digestive parasites have been developed recently, including multiplex PCR assays able to identify multiple parasites at once. Several studies have demonstrated that the efficacy of these molecular methods is dependent on the specific protocols employed at each stage of the process including pretreatment, extraction and amplification.
View Article and Find Full Text PDFSci Rep
July 2024
Parasitology-Mycology Department, CHU Clermont-Ferrand, 3IHP, 58 Rue Montalembert, 63000, Clermont-Ferrand, France.
Nowadays, the use of qPCR for the diagnosis of intestinal microsporidiosis is increasing. There are several studies on the evaluation of qPCR performance but very few focus on the stool pretreatment step before DNA extraction, which is nevertheless a crucial step. This study focuses on the mechanical pretreatment of stools for Enterocytozoon bieneusi spores DNA extraction.
View Article and Find Full Text PDFBMC Genomics
March 2024
Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, P.O. Box 50110, Zambia.
Sci Rep
October 2023
Laboratory of Molecular Diagnostics, AML - Sonic Healthcare Benelux, Antwerp, Belgium.
Cutaneous warts are benign skin lesions caused by the human papillomavirus (HPV). Even though they are considered benign, they can have a considerable impact on the quality of life and cause serious illness in certain immunocompromised populations. Studies have shown that the efficacy of wart treatment is dependent on the causative HPV type.
View Article and Find Full Text PDFViruses
August 2021
BC Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada.
Despite the effectiveness of direct-acting antiviral agents in treating hepatitis C virus (HCV), cases of treatment failure have been associated with the emergence of resistance-associated substitutions. To better guide clinical decision-making, we developed and validated a near-whole-genome HCV genotype-independent next-generation sequencing strategy. HCV genotype 1-6 samples from direct-acting antiviral agent treatment-naïve and -treated HCV-infected individuals were included.
View Article and Find Full Text PDF